Valuation: RAPT Therapeutics, Inc.

Market Cap 939M 838M 782M 710M 1.34B 90.9B 1.35B 9.39B 3.67B 46.19B 3.52B 3.45B 149B P/E 2023
-8.16x
P/E 2024 -0.5x
Enterprise Value 712M 636M 593M 539M 1.01B 68.96B 1.02B 7.12B 2.79B 35.04B 2.67B 2.62B 113B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
96.87%
Yield 2023 *
-
Yield 2024 -
1 day+0.07%
Current year+71.30%
Current year 29.77
Extreme 29.77
58.02
1 year 24.25
Extreme 24.25
58.02
3 years 5.67
Extreme 5.6652
218.8
5 years 5.67
Extreme 5.6652
325.92
10 years 5.67
Extreme 5.6652
409.68
Manager TitleAgeSince
President - 03/03/2026
Treasurer - 03/03/2026
Director TitleAgeSince
Director/Board Member - 03/03/2026
Director/Board Member - 03/03/2026
Date Insider Type Main position Quantity % Market Cap. Importance
3/3/26 Tender

Chief Technology Officer

164,742 0.5945%
3/3/26 Tender

Chief Financial Officer

205,703 0.7423%
3/3/26 Tender

Director

59,858 0.2160%
Change 5-day change 1-year change 3-year change Capi.($)
+0.07%-.--%+99.93%-52.35% 1.79B
-3.19%-3.19%+44.60%+87.98% 74.68B
-15.86%-16.16%+2.68%+51.09% 58.7B
-2.39%+0.50%+3.41%+31.33% 48.36B
-5.72%-8.01%+296.07%+643.62% 43.05B
+0.22%-0.98%+28.69%+29.38% 42.48B
-4.07%-3.08%-0.96%+101.24% 41.39B
-2.13%+1.07%+7.51%+50.31% 31.29B
-3.27%-4.73%-13.18%-15.59% 23.93B
-1.48%-8.11%-38.33%+307.12% 22.22B
Average -3.82%-2.35%+43.04%+123.41% 38.79B
Weighted average by Cap. -4.84%-1.87%+43.38%+134.48%

Financials

2023 2024
Net sales - -
Net income -117M -104M -97.3M -88.39M -166M -11.31B -168M -1.17B -457M -5.75B -439M -429M -18.49B -130M -116M -108M -98.28M -185M -12.58B -187M -1.3B -508M -6.39B -488M -477M -20.55B
Net Debt -152M -136M -127M -115M -216M -14.72B -218M -1.52B -594M -7.48B -571M -558M -24.05B -227M -202M -189M -171M -323M -21.94B -326M -2.27B -886M -11.15B -851M -832M -35.86B
Projected Income Statement - Annual - RAPT Therapeutics, Inc.
Logo RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Employees
60
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RAPT Stock